Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mohs Surgery | 8 | 2018 | 98 | 2.820 |
Why?
|
| Dermatologic Surgical Procedures | 2 | 2023 | 106 | 1.470 |
Why?
|
| Skin Neoplasms | 11 | 2024 | 4654 | 1.290 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2019 | 71 | 1.100 |
Why?
|
| Nail Diseases | 2 | 2015 | 40 | 0.960 |
Why?
|
| Nose | 2 | 2023 | 192 | 0.940 |
Why?
|
| Rhinoplasty | 2 | 2023 | 148 | 0.860 |
Why?
|
| Skin Transplantation | 2 | 2013 | 173 | 0.850 |
Why?
|
| Counseling | 1 | 2023 | 381 | 0.760 |
Why?
|
| Cicatrix | 2 | 2012 | 208 | 0.690 |
Why?
|
| Acrospiroma | 1 | 2019 | 13 | 0.690 |
Why?
|
| Skin | 2 | 2018 | 1259 | 0.680 |
Why?
|
| Fissure in Ano | 1 | 2018 | 8 | 0.650 |
Why?
|
| Vulvar Diseases | 1 | 2018 | 17 | 0.650 |
Why?
|
| Facial Neoplasms | 1 | 2019 | 84 | 0.650 |
Why?
|
| Infliximab | 1 | 2018 | 130 | 0.630 |
Why?
|
| Alternariosis | 1 | 2016 | 1 | 0.590 |
Why?
|
| Leg Dermatoses | 1 | 2016 | 7 | 0.590 |
Why?
|
| Immunocompetence | 1 | 2016 | 75 | 0.570 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 181 | 0.560 |
Why?
|
| Drug Storage | 1 | 2016 | 29 | 0.550 |
Why?
|
| Security Measures | 1 | 2015 | 5 | 0.550 |
Why?
|
| Drug Contamination | 1 | 2016 | 52 | 0.550 |
Why?
|
| Syringes | 1 | 2016 | 42 | 0.550 |
Why?
|
| Lidocaine | 1 | 2016 | 76 | 0.540 |
Why?
|
| Skin Diseases, Genetic | 1 | 2015 | 8 | 0.540 |
Why?
|
| Contracture | 1 | 2015 | 32 | 0.530 |
Why?
|
| Epinephrine | 1 | 2016 | 255 | 0.510 |
Why?
|
| Dermatology | 1 | 2015 | 70 | 0.510 |
Why?
|
| Methotrexate | 1 | 2018 | 999 | 0.510 |
Why?
|
| Anesthetics, Local | 1 | 2016 | 163 | 0.500 |
Why?
|
| Photography | 1 | 2015 | 139 | 0.500 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2015 | 209 | 0.500 |
Why?
|
| Crohn Disease | 1 | 2018 | 351 | 0.490 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 450 | 0.480 |
Why?
|
| Cyanoacrylates | 1 | 2013 | 41 | 0.480 |
Why?
|
| Models, Anatomic | 1 | 2015 | 154 | 0.470 |
Why?
|
| Tissue Adhesives | 1 | 2013 | 51 | 0.470 |
Why?
|
| Peripheral Nerves | 1 | 2014 | 159 | 0.460 |
Why?
|
| Nails | 1 | 2013 | 36 | 0.460 |
Why?
|
| Bandages | 1 | 2013 | 71 | 0.440 |
Why?
|
| Zinc Oxide | 1 | 2012 | 10 | 0.430 |
Why?
|
| Ointments | 1 | 2012 | 27 | 0.430 |
Why?
|
| Sunscreening Agents | 1 | 2012 | 33 | 0.430 |
Why?
|
| Skin Diseases | 1 | 2015 | 349 | 0.430 |
Why?
|
| Ear Neoplasms | 1 | 2013 | 59 | 0.430 |
Why?
|
| Eyelid Neoplasms | 1 | 2014 | 191 | 0.410 |
Why?
|
| Bowen's Disease | 1 | 2011 | 10 | 0.410 |
Why?
|
| Surgical Flaps | 1 | 2018 | 927 | 0.400 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2013 | 272 | 0.390 |
Why?
|
| Ochronosis | 1 | 2010 | 2 | 0.390 |
Why?
|
| Explosive Agents | 1 | 2010 | 4 | 0.380 |
Why?
|
| Nose Neoplasms | 1 | 2013 | 229 | 0.380 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2014 | 436 | 0.370 |
Why?
|
| Clinical Competence | 1 | 2018 | 1270 | 0.360 |
Why?
|
| Metals | 1 | 2010 | 155 | 0.350 |
Why?
|
| Postoperative Care | 1 | 2013 | 739 | 0.330 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 5687 | 0.320 |
Why?
|
| Carcinoma in Situ | 1 | 2011 | 487 | 0.310 |
Why?
|
| Choroid Neoplasms | 1 | 2007 | 41 | 0.300 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2014 | 5437 | 0.290 |
Why?
|
| Postoperative Hemorrhage | 1 | 2008 | 162 | 0.290 |
Why?
|
| Fibrinolytic Agents | 1 | 2008 | 324 | 0.260 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2992 | 0.260 |
Why?
|
| Humans | 26 | 2024 | 261506 | 0.240 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2024 | 51 | 0.230 |
Why?
|
| Wound Healing | 2 | 2023 | 815 | 0.230 |
Why?
|
| Population Health | 1 | 2024 | 51 | 0.220 |
Why?
|
| Biopsy | 2 | 2019 | 3443 | 0.190 |
Why?
|
| Melanoma | 3 | 2024 | 5317 | 0.190 |
Why?
|
| Suture Techniques | 1 | 2023 | 319 | 0.190 |
Why?
|
| Chin | 1 | 2019 | 16 | 0.170 |
Why?
|
| Roman World | 1 | 2018 | 2 | 0.170 |
Why?
|
| Greece, Ancient | 1 | 2018 | 11 | 0.170 |
Why?
|
| History, Medieval | 1 | 2018 | 30 | 0.160 |
Why?
|
| Aged | 9 | 2019 | 70117 | 0.160 |
Why?
|
| History, Ancient | 1 | 2018 | 68 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 3976 | 0.160 |
Why?
|
| Retrospective Studies | 6 | 2023 | 37905 | 0.160 |
Why?
|
| History, 19th Century | 1 | 2018 | 154 | 0.160 |
Why?
|
| India | 1 | 2018 | 301 | 0.150 |
Why?
|
| Econazole | 1 | 2016 | 2 | 0.150 |
Why?
|
| Granuloma | 1 | 2018 | 154 | 0.140 |
Why?
|
| Male | 11 | 2019 | 123000 | 0.140 |
Why?
|
| Itraconazole | 1 | 2016 | 77 | 0.140 |
Why?
|
| Physical Examination | 1 | 2018 | 299 | 0.140 |
Why?
|
| Europe | 1 | 2018 | 649 | 0.140 |
Why?
|
| Buffers | 1 | 2016 | 44 | 0.140 |
Why?
|
| Antirheumatic Agents | 1 | 2018 | 167 | 0.140 |
Why?
|
| Colony Count, Microbial | 1 | 2016 | 149 | 0.140 |
Why?
|
| Bicarbonates | 1 | 2016 | 130 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2018 | 574 | 0.130 |
Why?
|
| Hip Joint | 1 | 2015 | 54 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2018 | 467 | 0.130 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 4744 | 0.130 |
Why?
|
| Vasoconstrictor Agents | 1 | 2016 | 151 | 0.130 |
Why?
|
| Vitamin A | 1 | 2015 | 94 | 0.130 |
Why?
|
| Skin Aging | 1 | 2015 | 56 | 0.130 |
Why?
|
| Range of Motion, Articular | 1 | 2015 | 144 | 0.130 |
Why?
|
| Eccrine Glands | 1 | 2014 | 5 | 0.120 |
Why?
|
| Drug Combinations | 1 | 2016 | 621 | 0.120 |
Why?
|
| Hair Follicle | 1 | 2014 | 64 | 0.120 |
Why?
|
| Frozen Sections | 1 | 2014 | 105 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 383 | 0.120 |
Why?
|
| Steroids | 1 | 2015 | 356 | 0.120 |
Why?
|
| Female | 10 | 2018 | 141928 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2018 | 32848 | 0.110 |
Why?
|
| Pressure | 1 | 2013 | 215 | 0.110 |
Why?
|
| Life Expectancy | 1 | 2012 | 129 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 29902 | 0.100 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2014 | 330 | 0.100 |
Why?
|
| Administration, Topical | 1 | 2012 | 257 | 0.100 |
Why?
|
| Antifungal Agents | 1 | 2016 | 834 | 0.090 |
Why?
|
| Fibrosis | 1 | 2014 | 793 | 0.090 |
Why?
|
| Postoperative Period | 1 | 2012 | 665 | 0.090 |
Why?
|
| Cytoplasmic Granules | 1 | 2010 | 89 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2015 | 2450 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 4314 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 6009 | 0.080 |
Why?
|
| Aging | 1 | 2015 | 1582 | 0.070 |
Why?
|
| Adolescent | 2 | 2018 | 31252 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 3981 | 0.070 |
Why?
|
| Orbital Neoplasms | 1 | 2007 | 224 | 0.060 |
Why?
|
| Inflammation | 1 | 2014 | 2522 | 0.060 |
Why?
|
| Adult | 3 | 2018 | 77950 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 7548 | 0.050 |
Why?
|
| Sutures | 1 | 2023 | 86 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 2315 | 0.050 |
Why?
|
| Time Factors | 1 | 2016 | 12926 | 0.050 |
Why?
|
| Middle Aged | 4 | 2015 | 86204 | 0.050 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2015 | 95 | 0.030 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2015 | 42 | 0.030 |
Why?
|
| Child | 1 | 2015 | 29154 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2015 | 365 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2024 | 6100 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 699 | 0.030 |
Why?
|
| Risk Factors | 1 | 2008 | 17523 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 7702 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 4557 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2015 | 1152 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 2352 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 34495 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 59536 | 0.010 |
Why?
|